Roche and reMYND Enter Strategic Alliance for Development of Disease Modifying Treatments for Neurodegeneration

ReMYND has partnered with Roche to develop its small molecule candidates that target tau and alpha-synuclein pathologies for the treatment of neurodegenerative disease. The joint R&D effort is expected to generate a lead drug candidate, which Roche will then develop clinically and commercialize worldwide.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail